Scott Gottlieb

Dear Research Advocate, Congress is making progress in reauthorizing the FDA user fee programs, which is good news. According to officials at FDA, if the July 31 deadline for the “UFA” reauthorizations is missed, “reduction in force” (RIF) notices will be sent to one-third of the staff who review medical devices and a full 70% of those who review “small molecule” prescription drugs. The impact would probably be at least that dramatic for CBER, the center that reviews biologics. If the process stalls (or looks likely to), we’ll let you know and provide advocacy options! During his confirmation hearing before the Senate HELP committee yesterday, FDA Commissioner nominee Dr. Scott Gottlieb...
Leading Experts Focus on the Challenges and Opportunities Affecting the Fight Against Cancer ALEXANDRIA, Va. ’€“ February 27, 2014 ’€“ A panel of leading health, economics and policy experts today discussed the prospects for a future where cancers are rendered manageable or even eradicated and the variables affecting progress toward that goal so that cancer patients are able to lead normal, productive lives ’€“ and thus be ’€œfree from’€ their cancers. The forum was hosted by Research!America and the Pancreatic Cancer Action Network. The event, titled, ’€œA World Free from Cancers: Probable, Possible, or Preposterous?’€ was held at the New York Academy of Sciences. Medical innovation has...

Sidebar Quote

America’s economic destiny lies in innovation, technology, science and research.
The Honorable John E. Porter